Teachers Retirement System of The State of Kentucky acquired a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 32,776 shares of the biopharmaceutical company’s stock, valued at approximately $2,610,000. Teachers Retirement System of The State of Kentucky owned 0.09% of Sage Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its position in Sage Therapeutics by 10,082.5% during the 1st quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock worth $203,482,000 after purchasing an additional 2,835,006 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in shares of Sage Therapeutics during the 1st quarter worth approximately $35,493,000. Marshall Wace North America L.P. acquired a new stake in shares of Sage Therapeutics in the 1st quarter valued at approximately $35,493,000. Point72 Asset Management L.P. lifted its holdings in shares of Sage Therapeutics by 512.9% in the 1st quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock valued at $28,094,000 after buying an additional 330,800 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Sage Therapeutics by 10.8% in the 1st quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares during the period.

Sage Therapeutics, Inc. (NASDAQ SAGE) opened at 62.30 on Monday. Sage Therapeutics, Inc. has a 12 month low of $38.30 and a 12 month high of $90.80. The stock has a 50 day moving average price of $80.26 and a 200-day moving average price of $74.83. The stock’s market cap is $2.33 billion.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same quarter in the prior year, the business posted ($1.08) earnings per share. On average, analysts expect that Sage Therapeutics, Inc. will post ($7.37) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/teachers-retirement-system-of-the-state-of-kentucky-acquires-shares-of-32776-sage-therapeutics-inc-sage/1602714.html.

A number of analysts recently weighed in on SAGE shares. Needham & Company LLC set a $95.00 price target on Sage Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. HC Wainwright increased their price objective on Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Cowen and Company reiterated a “buy” rating and issued a $100.00 price objective on shares of Sage Therapeutics in a research report on Friday, August 4th. Stifel Nicolaus began coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price objective for the company. Finally, Canaccord Genuity set a $110.00 target price on Sage Therapeutics and gave the company a “buy” rating in a report on Saturday, August 5th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $86.77.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.